摘要
目的研究低剂量地西他滨、高三尖杉酯碱联合CAG方案(阿糖胞苷、阿柔比星、重组人粒细胞集落刺激因子)(DHCAG方案)治疗急性髓系白血病(AML)患者的临床效果及安全性.方法回顾性分析解放军联勤保障部队第九二○医院2017年7月至2018年6月接受DHCAG方案治疗的19例AML患者资料.其中初治13例,既往治疗无效或复发6例;老年(≥60岁)患者2例;15例患者化疗前合并肺部感染,4例患者入院时肺部未见病灶.统计缓解情况及化疗相关不良反应.结果19例患者给予DHCAG方案治疗1个疗程后,16例完全缓解,1例部分缓解,2例未缓解,治疗总有效率为89.5%(17/19).4例化疗前肺部未见病变患者治疗后肺部亦未发生感染;15例治疗前肺部感染患者中,除1例肺部感染进展死亡外,其余14例为1~2级感染.7例发生出血,3例发生恶心、呕吐,均为1~2级.结论DHCAG方案治疗AML的缓解率高,不良反应可耐受.
Objective To evaluate the efficacy and safety of low-dose decitabine and homoharringtonine combined with CAG regimen (cytarabine, aclarubicin and recombinant human granulocyte colony-stimulating factor) (DHCAG regimen) in treatment of acute myeloid leukemia (AML). Methods Nineteen patients who were treated with DHCAG regimen in the 920th Hospital of Joint Logistics Support Force from July 2017 to June 2018 were retrospectively analyzed. Among them, 13 cases were newly diagnosed, 6 cases were ineffective or relapsed;2 cases were elderly (≥60 years old);15 cases had pulmonary infection before chemotherapy, and 4 cases had no lesions in the lungs when admitted to hospital. The remission rate and chemotherapy-related adverse reactions were analyzed. Results After 19 patients received one course of DHCAG regimen, 16 patients had complete remission, 1 patient had partial remission, 2 patients had no remission, and the overall response rate was 89.5% (17/19). Four patients with undetected lung disease before chemotherapy had no infection in the lungs after treatment. Among 15 patients with pulmonary infection before treatment, 1 patient died of pulmonary infection progress, the remaining 14 cases were grade 1-2 infection. 7 cases had bleeding, and 3 cases had nausea and vomiting, all of which were grade 1-2. Conclusion The remission rate of DHCAG regimen in treatment of AML is high, and its adverse reactions are tolerable.
作者
刘林
黄小丽
王三斌
罗乐
袁忠涛
Liu Lin;Huang Xiaoli;Wang Sanbin;Luo Le;Yuan Zhongtao(Department of Hematology,the 920th Hospital of Joint Logistics Support Force,Kunming 650500,China;Clinical College of the 920th Hospital of Joint Logistics Support Force,Kunming Medical University,Kunming 650500,China)
出处
《白血病．淋巴瘤》
CAS
2019年第8期479-484,共6页
Journal of Leukemia & Lymphoma
